NO314080B1 - NMDA (N-metyl-D-aspartat) antagonister, farmasöytisk preparat inneholdendedisse og anvendelse derav for fremstilling av et medikament - Google Patents

NMDA (N-metyl-D-aspartat) antagonister, farmasöytisk preparat inneholdendedisse og anvendelse derav for fremstilling av et medikament Download PDF

Info

Publication number
NO314080B1
NO314080B1 NO19991533A NO991533A NO314080B1 NO 314080 B1 NO314080 B1 NO 314080B1 NO 19991533 A NO19991533 A NO 19991533A NO 991533 A NO991533 A NO 991533A NO 314080 B1 NO314080 B1 NO 314080B1
Authority
NO
Norway
Prior art keywords
compound
compound according
dichloroindol
acid
propenoic acid
Prior art date
Application number
NO19991533A
Other languages
English (en)
Norwegian (no)
Other versions
NO991533D0 (no
NO991533L (no
Inventor
Boyd L Harrison
Raymond S Gross
Bruce M Baron
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO991533D0 publication Critical patent/NO991533D0/no
Publication of NO991533L publication Critical patent/NO991533L/no
Publication of NO314080B1 publication Critical patent/NO314080B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19991533A 1996-09-30 1999-03-29 NMDA (N-metyl-D-aspartat) antagonister, farmasöytisk preparat inneholdendedisse og anvendelse derav for fremstilling av et medikament NO314080B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72317596A 1996-09-30 1996-09-30
PCT/US1997/014486 WO1998014427A1 (en) 1996-09-30 1997-08-18 Nmda (n-methyl-d-aspartate) antagonists

Publications (3)

Publication Number Publication Date
NO991533D0 NO991533D0 (no) 1999-03-29
NO991533L NO991533L (no) 1999-05-28
NO314080B1 true NO314080B1 (no) 2003-01-27

Family

ID=24905175

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991533A NO314080B1 (no) 1996-09-30 1999-03-29 NMDA (N-metyl-D-aspartat) antagonister, farmasöytisk preparat inneholdendedisse og anvendelse derav for fremstilling av et medikament

Country Status (18)

Country Link
EP (1) EP0929521B1 (de)
JP (1) JP2001501221A (de)
KR (1) KR20000048715A (de)
CN (1) CN1139572C (de)
AR (1) AR009374A1 (de)
AT (1) ATE309215T1 (de)
AU (1) AU732997B2 (de)
BR (1) BR9712144A (de)
CA (1) CA2266556C (de)
DE (1) DE69734594T2 (de)
DK (1) DK0929521T3 (de)
HU (1) HUP0000882A3 (de)
IL (1) IL129187A0 (de)
NO (1) NO314080B1 (de)
NZ (1) NZ334343A (de)
TW (1) TW492958B (de)
WO (1) WO1998014427A1 (de)
ZA (1) ZA978602B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053849A1 (en) * 1999-06-16 2001-12-20 Mary Jeanne Kreek Plural biological sample arrays, and preparation and uses thereof
KR20030060771A (ko) 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US7820688B2 (en) 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
AU2008315651B2 (en) * 2007-10-22 2012-12-13 Orchid Research Laboratories Limited Histone deacetylase inhibitors
KR20120123089A (ko) 2010-02-16 2012-11-07 화이자 인코포레이티드 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올
CA3146163A1 (en) 2019-07-08 2021-01-14 University Of Health Sciences & Pharmacy In St. Louis G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment
CN121695288A (zh) 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU216787B (hu) * 1990-07-16 1999-08-30 Merrell Dow Pharmaceuticals Inc. Eljárás excitátoros aminosav-antagonista hatású indolszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
WO1994027964A1 (en) * 1993-05-27 1994-12-08 Merrell Dow Pharmaceuticals Inc. 3-(indol-3-yl) propenoic acid derivatives and as nmda antagonists
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
AU732997B2 (en) 2001-05-03
EP0929521B1 (de) 2005-11-09
TW492958B (en) 2002-07-01
CA2266556A1 (en) 1998-04-09
EP0929521A1 (de) 1999-07-21
AR009374A1 (es) 2000-04-12
WO1998014427A1 (en) 1998-04-09
AU4071897A (en) 1998-04-24
HUP0000882A3 (en) 2001-04-28
NO991533D0 (no) 1999-03-29
DK0929521T3 (da) 2006-03-27
ATE309215T1 (de) 2005-11-15
ZA978602B (en) 1998-03-30
NO991533L (no) 1999-05-28
IL129187A0 (en) 2000-02-17
DE69734594D1 (en) 2005-12-15
CN1139572C (zh) 2004-02-25
NZ334343A (en) 2001-01-26
HUP0000882A2 (hu) 2000-09-28
CN1232452A (zh) 1999-10-20
CA2266556C (en) 2007-11-06
JP2001501221A (ja) 2001-01-30
KR20000048715A (ko) 2000-07-25
BR9712144A (pt) 1999-08-31
DE69734594T2 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
ES2350959T3 (es) Moduladores de bencimidazol de vr1.
US20090176883A1 (en) TRPA1 Antagonists
EA007493B1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
TW200836743A (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
JP2010526026A (ja) ｐ３８αＭＡＰＫ阻害剤としてのピリドン誘導体
NO177139B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-amidoindolylderivater
TW200821286A (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
JP3716217B2 (ja) β３アゴニスト及びその使用
JPH09512528A (ja) バソプレッシン拮抗物質としてのベンズアミド誘導体
FR2804114A1 (fr) Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
EP0929521B1 (de) Nmda (n-methyl-d-aspartate) antagonists
TWI441630B (zh) 曲馬朵（Ｔｒａｍａｄｏｌ）和可舒葆（Ｃｏｘｉｂ）之共結晶物
UA80670C2 (en) Indole derivatives, process the production thereof, medicaments based thereon, method for treatment tumours
JP3168566B2 (ja) Ｎｍｄａ拮抗剤
US5922752A (en) NMDA (n-methyl-d-aspartate) antagonists
EA017007B1 (ru) Соединения 5-(гетероциклил)алкил-n-(арилсульфонил)индола и их применение в качестве лигандов 5-ht
TWI327140B (en) Pyrimidine derivatives
TWI659022B (zh) 作為d-胺基酸氧化酶(daao)抑制劑之新穎經取代苯并咪唑衍生物
US5981553A (en) Heterocycle substituted propenoic acid derivatives as NMDA antagonist
MXPA97003146A (en) Derivatives of propenoic acid substituted conheterocicle as n antagonists
MXPA99002983A (en) Nmda (n-methyl-d-aspartate) antagonists
KR100504647B1 (ko) 오피에이트 수용체 리간드로서의 3-아자비시클로[3.1.0.]헥산 유도체